Description
DECREASE FUNDS FOR RADIOPHARMACEUTICALS TO CLOSE OUT OPTION YEAR, FY13
Base award description: RADIOPHARMACEUTICALS FOR RLRVAMC
Modification chain · 6 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2011-10-01+$492,748= $492,748
- Mod P000022012-09-12-$139,020= $353,728
- Mod P000012012-10-01+$516,078= $869,806
- Mod P000032012-12-10-$21,182= $848,624
- Mod P000042013-08-27-$180,000= $668,624
- Mod P000052013-12-30-$12,569= $656,055
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2011-10-01 | +$492,748 | $492,748 | RADIOPHARMACEUTICALS FOR RLRVAMC |
| Mod P00002· FUNDING ONLY ACTION | 2012-09-12 | −$139,020 | $353,728 | REDUCTION IN ESTIMATED QUANTITIES - RADIOPHARMACEUTICALS FOR RLRVAMC |
| Mod P00001· EXERCISE AN OPTION | 2012-10-01 | +$516,078 | $869,806 | RADIOPHARMACEUTICALS FOR RLRVAMC OPT YR 1 |
| Mod P00003· FUNDING ONLY ACTION | 2012-12-10 | −$21,182 | $848,624 | DECREASE FUNDS FOR RADIOPHARMACEUTICALS BASE YEAR, FY12 |
| Mod P00004· FUNDING ONLY ACTION | 2013-08-27 | −$180,000 | $668,624 | DECREASE FUNDS FOR RADIOPHARMACEUTICALS OPTION YEAR, FY13 |
| Mod P00005· CLOSE OUT | 2013-12-30 | −$12,569 | $656,055 | DECREASE FUNDS FOR RADIOPHARMACEUTICALS TO CLOSE OUT OPTION YEAR, FY13 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DR3USD14LYJ4)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25026N0072 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $350,000 | FY2026 |
| 36C25025N0041 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $350,003 | FY2025 |
| 36C25024N0057 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $305,179 | FY2024 |
| 36C25023D0083 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36C25019P0752 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $11,904 | FY2019 |
| 36C25019P0558 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $36,393 | FY2019 |
Other recipients under 6505 from 583-INDIANAPOLIS (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25116F0847 | ACTELION PHARMACEUTICALS US, INC. | 583-INDIANAPOLIS | $4,614 | FY2016 |
| VA25116F0730 | CSL BEHRING L.L.C. | 583-INDIANAPOLIS | $26,724 | FY2016 |
| VA25116F0509 | CSL BEHRING L.L.C. | 583-INDIANAPOLIS | $26,724 | FY2016 |
| VA25116F0406 | ROCHE DIAGNOSTICS CORPORATION | 583-INDIANAPOLIS | $17,601 | FY2016 |
| VA25116P0414 | ASD SPECIALTY HEALTHCARE, LLC | 583-INDIANAPOLIS | $35,317 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25112J0012_3600_VA251P1142_3600 · retrieved 2026-09-26.